Sensipar Related Published Studies
Well-designed clinical trials related to Sensipar (Cinacalcet)
Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. [2008.10]
Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study. [2008.08]
Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. [2008.05.27]
An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. [2008.04]
Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. [2008.04]
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. [2008.01]
Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. [2007.10]
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. [2007.09]
Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. [2007.02]
Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin. [2007]
Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. [2007]
First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. [2005.09]
Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. [2005.07]
Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. [2005.03]
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. [2005.02]
Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. [2005.01]
Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. [2004.12]
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. [2004.04.08]
The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. [2003.12]
Well-designed clinical trials possibly related to Sensipar (Cinacalcet)
Modification of cardiovascular risk in hemodialysis patients: An evidence-based review. [2007.01]
The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. [2003.03]
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. [2003.01]
The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. [2002.04]
Other research related to Sensipar (Cinacalcet)
Cinacalcet HCl and Concurrent Low-dose Vitamin D Improves Treatment of Secondary Hyperparathyroidism in Dialysis Patients Compared with Vitamin D Alone: The ACHIEVE Study Results. [2008.10.22]
Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. [2008.08.15]
Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis. [2008.08.01]
[Cinacalcet - an allosteric enhancer at the Ca2+-receptor] [2008.08]
Use of cinacalcet HCl to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism. [2008.07]
Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. [2008.07]
A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. [2008.06]
Cinacalcet for the treatment of primary hyperparathyroidism. [2008.04]
Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. [2008.04]
Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis. [2008.04]
[Cinacalcet in the therapy of secondary hyperparathyroidism--own experiences] [2008.04]
[Treatment of secondary hyperparathyroidism in renal insufficiency: role of calcitriol, sevelamer and cinacalcet] [2008.03.05]
Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan. [2008.03]
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. [2008.03]
Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy. [2008.02]
Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. [2008.02]
[Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism] [2008.01]
[Basic and clinical aspects of calcimimetics. The JSDT guideline and cinacalcet hydrochloride] [2008.01]
[Basic and clinical aspects of calcimimetics. Cinacalcet, effect and mechanisms of action] [2008.01]
Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. [2008.01]
Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. [2008.01]
Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. [2008]
Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report. [2007.12]
Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. [2007.10]
Hypercalciuria induced by a high dose of cinacalcet in a renal-transplant recipient. [2007.10]
Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. [2007.09]
Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. [2007.08.23]
Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. [2007.08]
Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. [2007.07]
Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy. [2007.07]
Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. [2007.06]
Cinacalcet in the management of tumor-induced osteomalacia. [2007.06]
Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. [2007.06]
Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. [2007.05.17]
The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. [2007.05]
The Pharmacokinetics of Cinacalcet are Unaffected Following Consumption of High- and Low-Fat Meals. [2007.05]
The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. [2007.05]
Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. [2007.03.15]
Successful use of cinacalcet HCl in a patient with end-stage renal failure and refractory secondary hyperparathyroidism due to parathyromatosis. [2007.03]
Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. [2007.02]
Cinacalcet-associated cardiogenic shock in a patient with cardiomyopathy. [2007.02]
Cinacalcet-induced hungry bone syndrome. [2007.01]
[Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl] [2007.01]
Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism. [2007]
Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl. [2006.12]
Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet. [2006.12]
Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. [2006.11]
Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. [2006.10]
Achieving targets for bone and mineral metabolism: the impact of cinacalcet HCl in clinical practice. [2006.10]
Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. [2006.09.15]
Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. [2006.08]
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. [2006.07]
Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. [2006.05.08]
Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. [2006.05]
Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats. [2006.05]
A case of parathyroid carcinoma with hypercalcemia responsive to cinacalcet therapy. [2006.05]
Improvement in hypercalcemia with cinacalcet after kidney transplantation. [2006.03]
Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. [2006.03]
[Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism] [2006.01.03]
Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring. [2006]
Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. [2005.11]
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. [2005.10]
Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. [2005.10]
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. [2005.07]
The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. [2005.07]
Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. [2005.07]
1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. [2005.07]
Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. [2005.06]
Cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving hemodialysis. [2005.05]
The role of cinacalcet in treating secondary hyperparathyroidism. [2005.03]
Cinacalcet HCl: a novel therapeutic for hyperparathyroidism. [2005.03]
Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. [2005.02]
Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl. [2005.01]
No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara). [2005]
Cinacalcet hydrochloride. [2005]
Clinical experience with cinacalcet HCl. [2004.08]
Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism. [2003.08]
Cinacalcet hydrochloride (Amgen). [2003.06]
|
